Published in Indian J Med Res on September 01, 2012
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl (2006) 3.73
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant (2010) 2.73
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg (2009) 2.51
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg (2008) 2.31
Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg (2009) 2.30
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl (2005) 2.04
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology (2005) 2.04
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg (2003) 2.02
Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2007) 2.00
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol (2007) 1.97
A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg (2009) 1.97
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist (2005) 1.68
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant (2006) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
The continuing challenge of hepatic cancer in Asia. Surgeon (2005) 1.36
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol (2003) 1.36
Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol (2009) 1.35
Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg (2004) 1.35
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis (2008) 1.32
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol (2008) 1.30
Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg (2009) 1.29
Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant (2008) 1.27
Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol (2010) 1.26
Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol (2010) 1.23
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 1.22
Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother (2008) 1.22
Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol (2010) 1.21
Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (2009) 1.20
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol (2008) 1.18
Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant (2010) 1.18
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist (2010) 1.16
Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg (2009) 1.16
Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant (2006) 1.12
A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol (2009) 1.12
Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant (2009) 1.11
Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol (2007) 1.09
An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol (2010) 1.07
Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg (2008) 1.07
Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol (2009) 1.06
Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int (2010) 1.05
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol (2008) 1.05
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol (2010) 1.04
The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int (2009) 1.03
Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol (2006) 1.03
Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology (2003) 1.03
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther (2010) 1.03
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer (2009) 1.02
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int (2009) 1.01
Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01
Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res (2009) 1.00
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology (2006) 1.00
Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol (2008) 1.00
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol (2009) 0.99
Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant (2004) 0.98
Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl (2010) 0.97
Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc (2008) 0.97
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol (2006) 0.97
Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2010) 0.97
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol (2009) 0.96
Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg (2003) 0.96
Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology (2007) 0.95
The place of downstaging for hepatocellular carcinoma. J Hepatol (2010) 0.95
Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant (2005) 0.94
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther (2010) 0.94
Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg (2010) 0.92
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer (2008) 0.91
Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant (2008) 0.89
Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther (2010) 0.89
Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther (2009) 0.89
Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int (2007) 0.89
A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol (2009) 0.89
Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl (2008) 0.88
Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology (2008) 0.88
Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer (2009) 0.87
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Estimated reduction in cancer risk due to PAH exposures if source control measures during the 2008 Beijing Olympics were sustained. Environ Health Perspect (2011) 1.68
Catalytic asymmetric bromoamination of chalcones: highly efficient synthesis of chiral alpha-bromo-beta-amino ketone derivatives. Angew Chem Int Ed Engl (2010) 1.60
Two-year follow-up evaluation of surgical treatment for thoracolumbar fracture-dislocation. Spine (Phila Pa 1976) (2014) 1.44
Prophylaxis against hepatitis B virus recurrence after liver transplantation for hepatitis B virus-related end-stage liver diseases with severe hypersplenism and splenomegaly: role of splenectomy. J Surg Res (2012) 1.41
Black carbon emissions in China from 1949 to 2050. Environ Sci Technol (2012) 1.38
An Uncertainty Measure for Incomplete Decision Tables and Its Applications. IEEE Trans Cybern (2013) 1.38
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology (2014) 1.22
Emission of oxygenated polycyclic aromatic hydrocarbons from indoor solid fuel combustion. Environ Sci Technol (2011) 1.12
A case of clinically silent giant right pheochromocytoma and review of literature. Can Urol Assoc J (2012) 1.12
Donor vaccination: is it necessary to prevent hepatitis B virus recurrence after living donor liver transplantation? Liver Transpl (2014) 1.08
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis (2010) 1.06
Fibrin sealant for prevention of resection surface-related complications after liver resection in living liver donors. Ann Surg (2015) 1.06
Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci (2011) 1.02
The clinicopathological features of intraductal papillary neoplasms of the bile duct in a Chinese population. Dig Liver Dis (2011) 1.02
The changes of hepatic hemodynamics and functional hepatic reserve after splenectomy with periesophagogastric devascularization. Hepatogastroenterology (2009) 1.02
Donor safety in living donor liver transplantation: a single-center analysis of 300 cases. PLoS One (2013) 1.00
Assessment of tear film stability in dry eye with a newly developed keratograph. Cornea (2013) 0.99
Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLoS One (2012) 0.96
Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal cancer risk. PLoS One (2012) 0.93
Laser-filamentation-induced condensation and snow formation in a cloud chamber. Opt Lett (2012) 0.92
Highly enantioselective synthesis of tetrahydroquinolines via cobalt(II)-catalyzed tandem 1,5-hydride transfer/cyclization. Org Lett (2011) 0.91
Airborne particulates and polycyclic aromatic hydrocarbons (PAHs) in ambient air in Donghe, northern China. J Environ Sci Health A Tox Hazard Subst Environ Eng (2009) 0.89
Asymmetric iodoamination of chalcones and 4-aryl-4-oxobutenoates catalyzed by a complex based on scandium(III) and a N,N'-dioxide ligand. Chemistry (2011) 0.89
Continuous normothermic hemihepatic vascular inflow occlusion over 60 min for hepatectomy in patients with cirrhosis caused by hepatitis B virus. Hepatol Res (2007) 0.89
Intrahepatic venous collaterals formation following outflow block in adult-to-adult living donor liver transplantation. J Surg Res (2007) 0.87
Living donor liver transplantation for Budd-Chiari syndrome using cryopreserved vena cava graft in retrohepatic vena cava reconstruction. Liver Transpl (2006) 0.86
Bronchogenic cyst of the gastric fundus in a young woman. Dig Liver Dis (2009) 0.86
Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg (2013) 0.86
Strategies for interfacing inorganic nanocrystals with biological systems based on polymer-coating. Chem Soc Rev (2014) 0.85
Comparison of the outcomes of patients who underwent deceased-donor or living-donor liver transplantation after successful downstaging therapy. Eur J Gastroenterol Hepatol (2013) 0.85
Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol (2015) 0.84
A passive sampler with improved performance for collecting gaseous and particulate phase polycyclic aromatic hydrocarbons in air. Environ Sci Technol (2009) 0.83
Successful adult-to-adult living donor liver transplantation combined with a cadaveric split left lateral segment. Liver Transpl (2006) 0.83
Successful use of hepatitis B surface antigen-positive liver grafts in recipients with hepatitis B virus-related liver diseases. Liver Transpl (2011) 0.83
Comparison of laparoscopy-assisted and open donor right hepatectomy: a prospective case-matched study from china. J Gastrointest Surg (2013) 0.82
Expression of vascular endothelial growth factor and matrix metalloproteinase-2 correlates with the invasion and metastasis of hepatocellular carcinoma. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2003) 0.82
[Estimation formula of standard liver volume for Chinese adults]. Sichuan Da Xue Xue Bao Yi Xue Ban (2009) 0.82
Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study. Eur J Gastroenterol Hepatol (2014) 0.82
Synthesis of renewable high-density fuels using cyclopentanone derived from lignocellulose. Chem Commun (Camb) (2014) 0.82
Laser filamentation induced air-flow motion in a diffusion cloud chamber. Opt Express (2013) 0.82
Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria. Transpl Int (2014) 0.82
Risk factors for first-year hospital readmission after liver transplantation. Eur J Gastroenterol Hepatol (2015) 0.81
Enantioselective recognition of α-hydroxycarboxylic acids and N-Boc-amino acids by counterion-displacement assays with a chiral nickel(II) complex. Org Lett (2011) 0.81
A prospective randomized comparison of continuous hemihepatic with intermittent total hepatic inflow occlusion in hepatectomy for liver tumors. Hepatogastroenterology (2009) 0.81
A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol (2012) 0.81
A single institution experience with living donor liver transplantation for acute-on-chronic hepatitis B liver failure. Hepatogastroenterology (2011) 0.80
Preliminary experience for reducing biliary complication in adult-to-adult living donor liver transplantation using right lobe graft. Hepatol Res (2007) 0.80
Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg (2013) 0.80
Obstructive jaundice due to primary neurofibroma of the common bile duct. Dig Liver Dis (2009) 0.79
Solvent-free synthesis of C10 and C11 branched alkanes from furfural and methyl isobutyl ketone. ChemSusChem (2013) 0.79
Catalytic conversion of isophorone to jet-fuel range aromatic hydrocarbons over a MoO(x)/SiO2 catalyst. Chem Commun (Camb) (2015) 0.79
Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J (2010) 0.79
Successful treatment of Epstein-Barr Virus-associated haemophagocytic syndrome arising after living donor liver transplantation. Hepatol Res (2008) 0.79
MIR137 Regulates Starvation-Induced Autophagy by Targeting ATG7. J Mol Neurosci (2015) 0.78
Highly enantioselective alpha-chlorination of cyclic beta-ketoesters catalyzed by N,N'-dioxide using NCS as the chlorine source. Chem Commun (Camb) (2010) 0.78
Four-year follow-up of two chronic hepatitis B recipients of hepatitis B surface antigen-positive cadaveric liver grafts from asymptomatic carriers. Hepatol Res (2011) 0.78
Catalytic asymmetric Roskamp reaction of alpha-alkyl-alpha-diazoesters with aromatic aldehydes: highly enantioselective synthesis of alpha-alkyl-beta-keto esters. J Am Chem Soc (2010) 0.78
Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies. J Gastrointest Surg (2013) 0.78
Immediate Postoperative Low Platelet Counts After Living Donor Liver Transplantation Predict Early Allograft Dysfunction. Medicine (Baltimore) (2015) 0.78
Polycyclic aromatic hydrocarbons and organochlorine pesticides in surface soils from the Qinghai-Tibetan plateau. J Environ Monit (2010) 0.78
Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells. Exp Clin Transplant (2012) 0.77
[Construction of recombinant caspases-3 gene and the test of its apoptotic activity in pancreatic carcinoma cell strain]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2003) 0.77
Effects of separation distance on the charge transfer interactions in quantum dot-dopamine assemblies. Phys Chem Chem Phys (2015) 0.77
Donor morbidity including biliary complications in living-donor liver transplantation: a single center analysis of 283 cases. Transplantation (2012) 0.77
Systematic review of the safety of living liver donors. Hepatogastroenterology (2013) 0.77
Following up of liver transplantation using dual left grafts from living donors--one case. Hepatogastroenterology (2008) 0.77
Can primary LDLT be the alternative first line treatment for infant patients with biliary atresia? Hepatogastroenterology (2013) 0.77
Fate modeling of mercury species and fluxes estimation in an urban river. Environ Pollut (2013) 0.76
Analysis of causes of bullous keratopathy in East China: a 10-year retrospective study. Graefes Arch Clin Exp Ophthalmol (2011) 0.76
Prevention and treatment of rethrombosis after liver transplantation with an implantable pump of the portal vein. Liver Transpl (2010) 0.76
Highly enantioselective conjugate addition of thioglycolate to chalcones catalyzed by lanthanum: low catalyst loading and remarkable chiral amplification. Angew Chem Int Ed Engl (2010) 0.76
Hexachlorocyclohexanes (HCHs) in placenta and umbilical cord blood and dietary intake for women in Beijing, China. Environ Pollut (2013) 0.76
Investigation of ultrashort pulse laser ablation of solid targets by measuring the ablation-generated momentum using a torsion pendulum. Opt Express (2011) 0.75
Assessment of Lower Tear Meniscus. Optom Vis Sci (2016) 0.75
Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section. Medicine (Baltimore) (2017) 0.75
Adult to adult right lobe living donor liver transplantation: does biological relationship matter? Medicine (Baltimore) (2017) 0.75
A comprehensive study of the safety of using anti-hepatitis B core (Hbc) positive subjects in living donor liver transplants. Hepatogastroenterology (2013) 0.75
Obstructive jaundice secondary to haemobilia from calcifying fibrous pseudotumor. Dig Liver Dis (2011) 0.75